• BXN.AU

A novel Approach to healthcare,
extraordinary results




Our mission is to revolutionise the way the world approaches healthcare.
Our focus is on cannabis & psilocybin medicines, healthcare technology, and novel consumer health products.

Starting Materials & APIs

We work with certified cultivators and manufacturers around the world to deliver only the best APIs and starting materials

Wholesale Distribution

With operations in Australia, UK, Europe, Switzerland, Japan, Malaysia, and USA we serve clients across 5 continents

Manufacturing

Our ISO-accredited clean rooms and GMP standards in Australia, Czechia, Japan, and UK mean our wellness solutions and medicines are guaranteed to meet quality standards.

Brand Equity & IP

Over 15 years BXN has built globally recognized brands, trusted by businesses and consumers. These include: Bioxyne, PCC®, Dr. Watson®, Breathe Life Sciences, BLS Clinics, Apothecary CBD® and more

Who we are

Bioxyne is an Australian life sciences, pharmaceutical and consumer health products company. Our consumer health products have been developed and sold globally for more than 15 years.

Bioxyne is committed to bringing science to wellbeing – everything we do is underpinned by a strong clinical and scientific foundation.

Bioxyne is the parent company of Breathe Life Sciences, licensed by the Australian government to import, export, manufacture and wholesale Schedule 3,4 and 8 medicines.

BLS operates in Australia, Japan, UK, Europe manufacturing for and supplying cannabis and mushroom extracts and products B2B and B2C.

Play Video
1 X
Manufacturing & Warehouse Facilities
150 +
APIs, starting materials & health products
1 +
Shareholders
1 k+
Customers Served

Our Products

Explore our science and wellbeing hub

Bioxyne is an Australian life sciences and health products company. Our consumer health products have been developed and sold globally for more than 15 years.

Breathe Life Sciences (BLS Wholesalers PTY Ltd) is a leading Sponsor of medicinal cannabis in Australia supplying cultivators, manufacturers, pharmacies and patients nation wide. The Breathe Life Sciences Group was acquired by Bioxyne in May 2023 and is a 100% wholly owned subsidiary. 

What we stand for

We believe that medical cannabis can be a safer and more efficacious treatment for chronic pain.

We believe that psilocybin can be a safer and more efficacious treatment for depression, and various mental health conditions. 

Our mission is to expedite the adoption and acceptance of these new compounds, particularly in those who current treatments have failed, and to successfully gain marketing approval for the medicines we manufacture.  

As a licensed pharmaceutical sponsor in Australia Breathe Life Sciences operates in a highly regulated environment. Under our ODC and QLD Health licenses (BLS Wholesalers Pty Ltd) we import, warehouse, and supply bulk GACP starting materials to manufacturers and pharmacy, and GMP manufactured finished products to patients via special access pathways, following rigorous SOPs, controlling chain of custody and maintaining compliance with the use of secure pharmacy and inventory tracking technology.

 

BLS Clinics - Powered by Instant Scripts

In 2023, BLS launched its telemedicine platform, powered by Instant Scripts, Australia’s largest telehealth technology provider.

With a small army of authorized prescribers, and Instant Script’s 600,000 patient database, BLS Clinics is positioned to become a market leader in telehealth consultations for alternative medicines. 

BLS Wholesalers is our wholly owned subsidiary, licensed by TGA and ODC for import, export, warehouse, and wholesale of Schedules 3, 4, 8 medicines, with pending GMP certification and Schedule 9 license. 

Dr Watson® achieves FSA listing, and approval for exclusive Amazon Vendor pilot for CBD in UK, EU, Japan

In the UK and EU, Dr Watson CBD products are classed as Novel Foods by the FSA. Breathe Life Sciences and Dr Watson are one of only a dozen approved Amazon vendors for CBD products in the UK and EU.

Machine Learning Powered B2B Wholesale and Custody Technology

Through an exclusive business arrangement, Breathe Life Sciences is working with Europes leading B2B cannabis technology platform, CanXChange, to build greater market access for sponsors and manufacturers of medical cannabis, and pharmacies in Australia. 

CanXChange Australia, powered by BLS Wholesalers Pty

RECENT POSTS

Our News

Bioxyne's Breathe Life Sciences signs tech deal to bring B2B market technology platform and chain of custody tech to Australia

Bioxyne CEO and Breathe Life Sciences founder talks medical cannabis and mushrooms with Stock Insiders

Bioxyne's Dr Watson & BLS Clinics Sponsors Sydnery Rowing Club and Henley 2023

Have any Questions?

If you have any questions, please feel free to drop us a message or call use now!

What we stand for

We believe that medical cannabis can be a safer and more efficacious treatment for chronic pain.

We believe that psilocybin can be a safer and more efficacious treatment for depression, and various mental health conditions. 

Our mission is to expedite the adoption and acceptance of these new compounds, particularly in those who current treatments have failed, and to successfully gain marketing approval for the medicines we manufacture.  

As a licensed pharmaceutical sponsor in Australia Breathe Life Sciences operates in a highly regulated environment. Under our ODC and QLD Health licenses (BLS Wholesalers Pty Ltd) we import, warehouse, and supply bulk GACP starting materials to manufacturers and pharmacy, and GMP manufactured finished products to patients via special access pathways, following rigorous SOPs, controlling chain of custody and maintaining compliance with the use of secure pharmacy and inventory tracking technology.

 

Congratulations to Sydney rowing club
for reaching the semi finals

We Work With